참고문헌 (10)

1. 10.1016/0960-894X(96)00323-X Terrett, N. K., Bell, A. S.: Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorganic Med. Chem. Lett. 6(15), 1819 (1996). 

   상세보기

2. 10.1016/S0002-9149(99)00044-2 Webb, D. J., Freestone, S.: Sildenafil citrate and blood- pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am. J. Cardiol. 83(5 Suppl 1), 2 (1999). 

   상세보기

3. 10.1038/nature01914 Hwang, K. Y., Ro, S.: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425, 98 (2003). 

   상세보기

4. 10.1002/14651858.CD003382.pub3 Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., Hawton, K.: Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst. Rev. (5), CD003382 (2013). doi: 10.1002/14651858.CD003382.pub3. 

   

5. 10.1016/j.rmed.2014.01.003 Liang, Z.-A., Wang, R.-C.: Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir. Med. 108, 531 (2014). 

   상세보기

6. 10.1021/op9900683 Dale, D. J., Dunn, P. J., Hughes, M. L.: The chemical development of the commercial route to sildenafil: a case history. Org. Process Res. Dev. 4, 17 (2000). 

   상세보기

7. 10.1021/op040019c Dunn, P. J.: Synthesis of commercial phosphodiesterase(V) inhibitors. Org Process Res. Dev. 9, 88 (2005). 

   상세보기

8. Bell, A. S., Sandwich, K.: Pyrazolopyrimidinone antianginal agents, EP0463756 (1992). 

9. Czarnik, A. W., Reno: Deuterium enriched Sildenafil, US2009/0062298 (2009). 

10. 10.1055/s-0031-1296622 Schneider, F., Mattern-Dogru, E., Hillgenberg, M., Alken, R. G.: Changed phosphodiesterase selectivity and enhanced in vitro efficacy by selective deuteration of Sildenafil. Arzneimittelforschung 57(6), 293 (2007). 

    상세보기